FindTrial
Sign In

Role of rTMS in post-stoke spasticity.

To evaluate the effectiveness of add on repetitive transcranial magnetic stimulation (rTMS) in management of post-stroke spasticity a randomized control trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/08/036026
Enrollment
50
Registered
2021-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G811- Spastic hemiplegia

Interventions

Intervention1: repetitive transcranial magnetic stimulation (rTMS): Each treatment arm will consist of 3 daily treatment sessions. One treatment session will consist of 1000 pulses of 1 Hz rTMS at an

Sponsors

Aiims Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. First-time stroke 2. Stroke at least three months prior to onset of study with chronic sequela of spasticity 3. Stroke location- either cortical or subcortical 4. Stroke type- either hemorrhagic or ischemic 5. Stroke hemisphere- either left or right, dominant or non- dominant hemisphere 6. 18 years of age or older 7. Gender- either male or female 8. Ability to follow three-step directions 9. Demonstration of 10 degrees of active extension at the metacarpophalangeal joint and wrist of the paretic upper extremity 10. Sufficient ambulation or wheelchair mobility to allow subject to present to treatment and testing areas with minimum assistance

Exclusion criteria

Exclusion criteria: 1. History of seizure within the past two years 2. Inability to follow three-step directions 3. Anosognosia 4. Moderate to severe receptive aphasia 5. Inability to give informed consent 6. Premorbid spasticity or neurologic impairment prior to stroke 7. Co-morbidities impairing upper extremity function such as fracture or deformity 8. Indwelling metal or medical devices incompatible with TMS 9. Pregnancy 10. Bi-hemispheric or multifocal stroke 11. Severe dementia 12. Neurolytic injection within the 3 months prior to onset of study or planned neurolytic injection during study period

Design outcomes

Primary

MeasureTime frame
Change in Baseline modified Modified Ashworth Scale score from Day 1 (Pre-treatment) to Day 5 (Post-treatment), and at 1 monthTimepoint: 1 month—

Secondary

MeasureTime frame
Motor function improvement will be assessed through digital hand dynamometerTimepoint: 1 month—

Countries

India

Contacts

Public ContactDr Yuvraj Lahre

Aiims Bhubaneswar

bhoisanjeev@gmail.com9919787978

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026